Bispecific pd-l1 and cd40 binding molecules and uses thereof
AssigneeAptevo Research and Development LLC
InventorsPeter PAVLIK, Michelle H. NELSON, Matthew J. BAILEY, Lynda MISHER, Elizabeth R. HAGLIN, Secil FRANKE-WELCH, Hilario RAMOS, David BIENVENUE
Life of this patent
Estimating the term…
Abstract
Provided herein are bispecific antigen-binding molecules that bind to PD-L1 and/or CD40. Further provided herein are therapeutic uses of and methods of producing such molecules and related pharmaceutical compositions, nucleic acid molecules, expression vectors and host cells.
Claims51
A PD-L1 binding polypeptide that binds specifically to human PD-L1 wherein the PD-L1 binding polypeptide comprises, in order from amino terminus to carboxyl terminus or from carboxyl terminus to amino terminus,
- (a) a first binding domain;
- (b) a hinge region;
- (c) an immunoglobulin constant region;
- and
- (d) a second binding domain;
- wherein the first binding domain is a PD-L1 binding domain and the second binding domain binds an immunostimulatory protein;
- or
- wherein the first binding domain binds an immunostimulatory protein and the second binding domain is a PD-L1 binding domain.
A CD40 binding polypeptide that binds specifically to human CD40;
- wherein the CD40 binding polypeptide comprises, in order from amino terminus to carboxyl terminus or from carboxyl terminus to amino terminus,
- (a) a first binding domain;
- (b) a hinge region;
- (c) an immunoglobulin constant region;
- and
- (d) a second binding domain;
- wherein the first binding domain is a CD40 binding domain and the second binding domain binds a tumor-associated antigen;
- or
- wherein the first binding domain binds a tumor-associated antigen and the second binding domain is a CD40 binding domain.
A binding polypeptide that binds specifically to human PD-L1 and human CD40;
- wherein the binding polypeptide comprises, in order from amino terminus to carboxyl terminus or from carboxyl terminus to amino terminus,
- (a) a first binding domain;
- (b) a hinge region;
- (c) an immunoglobulin constant region;
- and
- (d) a second binding domain;
- wherein the first binding domain is a PD-L1 binding domain and the second binding domain is a CD40 binding domain;
- or
- wherein the first binding domain is a CD40 binding domain and the second binding domain is a PD-L1 binding domain.
Dependencies are inferred from the claim text.